Richmond Pharmacology was one of the last CROs to be founded in the UK. The vision was to create a new clinical study infrastructure: a unit nested in a hospital setting – at St George’s University of London – allowing clinicians to participate in high-end studies.  The profits were reinvested in the company or used to fund academic research.

Twenty years later, and the model has not changed – we recently established the Richmond Research Institute to provide a formal setting for academic studies in under-researched areas.

Our work has evolved from small molecules to monoclonal antibodies, RNA therapeutics and most recently gene editing.